NASDAQ$TMCI
Treace Medical Concepts Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024.
Treace Medical Concepts reported a 21% increase in revenue to $51.1 million for Q1 2024 compared to the same period in 2023. The company's gross margin was 80.2%. Net loss attributable to common stockholders was ($18.7) million, and the Adjusted EBITDA loss improved to ($8.3) million.
- Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023
- Gross margin of 80.2% in first quarter 2024
- First quarter 2024 net loss attributable to common stockholders was ($18.7) million compared to ($13.5) million for same period in 2023
- Adjusted EBITDA loss improved to ($8.3) million in first quarter 2024 compared to loss of ($10.0) million for same period in 2023
Headline financials
Revenue & EPS history
Treace · Revenue · Quarterly
$51.1M
Forward guidance
The Company now expects full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. The Company continues to expect to make significant improvement in Adjusted EBITDA for full-year 2024 and anticipates Adjusted EBITDA to improve approximately 50% compared to full-year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-5.8%
Avg return
Earnings day
-5.9%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
7 / 21 earnings
Positive
+43.3%
Q3 2024
Best reaction
-62.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +31.8% | +82.3% | |
| Q4 2025 | -11.0% | -30.0% | -41.9% | |
| Q3 2025 | -28.6% | -46.6% | -56.0% | |
| Q1 2025 | -9.5% | -10.9% | -22.9% | |
| Q4 2024 | -2.1% | +0.0% | -7.4% | |
| Q3 2024 | +43.3% | +48.1% | +42.7% | |
| Q2 2024 | +2.7% | -8.5% | -13.9% | |
| Q1 2024 | -62.8% | -60.9% | -45.5% | |
| Q4 2023 | -5.7% | -6.4% | -8.9% | |
| Q3 2023 | -42.1% | -32.0% | -11.4% | |
| Q2 2023 | -16.9% | -20.3% | -31.3% | |
| Q1 2023 | -5.5% | -4.9% | -0.9% | |
| Q4 2022 | +21.1% | +19.0% | +37.5% | |
| Q3 2022 | +1.9% | +16.1% | +13.7% | |
| Q2 2022 | -1.3% | +1.0% | +10.1% | |
| Q1 2022 | -14.4% | -30.2% | -9.3% | |
| Q4 2021 | -1.0% | -7.4% | -5.7% | |
| Q3 2021 | -0.8% | -6.6% | -28.5% | |
| Q2 2021 | -3.3% | -5.9% | -3.2% | |
| Q4 2020 | +4.7% | +14.9% | +11.5% | |
| Q1 2021 | +4.7% | +14.9% | +11.5% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro